Available online 10 December 2023

MEOX2 correlates with glioma malignancy and poor prognosis.

MEOX2 promotes glioma growth and temozolomide chemoresistance.

MEOX2 drives glioma chemoresistance by activating AKT signaling.

MEOX2 serves as a therapeutic target for glioma chemotherapeutic intervention.

© 2023 The Author(s). Published by Elsevier B.V. on behalf of Xi’an Jiaotong University.